{"id":41964,"date":"2018-01-30T18:36:06","date_gmt":"2018-01-30T16:36:06","guid":{"rendered":"https:\/\/newserver.fyb.de\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/"},"modified":"2018-01-30T18:36:06","modified_gmt":"2018-01-30T16:36:06","slug":"sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/","title":{"rendered":"SDAX candidate: Dermapharm brings 25% percent to the stock exchange"},"content":{"rendered":"<p>Berlin \u2014 The initial public offe\u00adring of <strong>Derm\u00ada\u00adph\u00adarm<\/strong> has star\u00adted. The offer period runs until Febru\u00adary 8. The manu\u00adfac\u00adtu\u00adrer has set a range of 26 to 30 euros. The total volume of the offe\u00adring is thus expec\u00adted to be around EUR 350 to 404 million. Since <strong>Wilhelm Beier (photo),<\/strong> the company\u2019s CEO, only wants to place 25 percent of the shares, he could make a good cut compared to the sale plan\u00adned in&nbsp;2016.<\/p>\n<p>A total of 13.455 million shares are to be offe\u00adred to inves\u00adtors. Of these, 3.84 million will come from a capi\u00adtal increase and 7.86 million from Beier and his family. In addi\u00adtion, an over-allot\u00adment option (green\u00adshoe) for 1.755 million shares owned by the company foun\u00adder is plan\u00adned. Should all shares be sold, the free float would amount to appro\u00adxi\u00adm\u00adately 25 percent. Derm\u00ada\u00adph\u00adarm would thus be valued at 1.4 to 1.6 billion euros. The plan\u00adned sale to finan\u00adcial inves\u00adtors, which was later cancel\u00adled, was worth 1.1 billion euros a year ago. Accor\u00adding to media reports, the finan\u00adcial inves\u00adtors BC Part\u00adners and Nordic Capi\u00adtal each offe\u00adred slightly more than one billion euros.&nbsp;.<\/p>\n<p>The money raised in the IPO \u2014 around 100 to 115 million euros from the capi\u00adtal increase \u2014 is to be used to expand a produc\u00adtion faci\u00adlity, and a new produc\u00adtion plant is also to be built in Austria. Derm\u00ada\u00adph\u00adarm also intends to expand inter\u00adna\u00adtio\u00adnally. Further acqui\u00adsi\u00adti\u00adons are plan\u00adned, as well as bran\u00adches in the Bene\u00adlux count\u00adries and in the Czech Repu\u00adblic and Slova\u00adkia. For share buyers, 50 to 60 percent of profits are to be paid out as divi\u00addends in the very first&nbsp;year.<\/p>\n<p><strong>New products in the pipeline<\/strong><br>\nNew products are also spur\u00adring expan\u00adsion, with 40 curr\u00adently in the plan\u00adning and imple\u00admen\u00adta\u00adtion stages. Of these, 28 are to be brought to market by 2023. In order to make itself look good for the IPO, Derm\u00ada\u00adph\u00adarm acqui\u00adred two compa\u00adnies, Tromms\u00addorff and Strath\u00admann, at the end of last year. Recently, Bio-Di\u00e4t Berlin has also become part of Dermapharm.<\/p>\n<p><strong>About Derm\u00ada\u00adph\u00adarm<\/strong><br>\nDerm\u00ada\u00adph\u00adarm manu\u00adfac\u00adtures off-patent drugs (gene\u00adrics) and sells them prima\u00adrily in Germany, a market which in and of itself can be conside\u00adred very solid, albeit compe\u00adti\u00adtive. The vitamin D prepa\u00adra\u00adtion Dekris\u00adtol 20,000 I.U. accoun\u00adted for around 7.5 percent of sales in&nbsp;2016.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Berlin \u2014 The initial public offe\u00adring of Derm\u00ada\u00adph\u00adarm has star\u00adted. The offer period runs until Febru\u00adary 8. The manu\u00adfac\u00adtu\u00adrer has set a range of 26 to 30 euros. The total volume of the offe\u00adring is thus expec\u00adted to be around EUR 350 to 404 million. Since Wilhelm Beier (photo), the company\u2019s CEO, only wants&nbsp;to&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":41972,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-41964","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-deals-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>SDAX candidate: Dermapharm brings 25% percent to the stock exchange - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SDAX candidate: Dermapharm brings 25% percent to the stock exchange - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Berlin \u2014 The initial public offe\u00adring of Derm\u00ada\u00adph\u00adarm has star\u00adted. The offer period runs until Febru\u00adary 8. The manu\u00adfac\u00adtu\u00adrer has set a range of 26 to 30 euros. The total volume of the offe\u00adring is thus expec\u00adted to be around EUR 350 to 404 million. Since Wilhelm Beier (photo), the company\u2019s CEO, only wants to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-30T16:36:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/01\/a-derma-e1517330055322.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"319\" \/>\n\t<meta property=\"og:image:height\" content=\"252\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"SDAX candidate: Dermapharm brings 25% percent to the stock exchange\",\"datePublished\":\"2018-01-30T16:36:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/\"},\"wordCount\":362,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/01\/a-derma-e1517330055322.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/\",\"url\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/\",\"name\":\"SDAX candidate: Dermapharm brings 25% percent to the stock exchange - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/01\/a-derma-e1517330055322.jpg\",\"datePublished\":\"2018-01-30T16:36:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/01\/a-derma-e1517330055322.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/01\/a-derma-e1517330055322.jpg\",\"width\":319,\"height\":252},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SDAX candidate: Dermapharm brings 25% percent to the stock exchange\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SDAX candidate: Dermapharm brings 25% percent to the stock exchange - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/","og_locale":"en_US","og_type":"article","og_title":"SDAX candidate: Dermapharm brings 25% percent to the stock exchange - FYB Financial Yearbook","og_description":"Berlin \u2014 The initial public offe\u00adring of Derm\u00ada\u00adph\u00adarm has star\u00adted. The offer period runs until Febru\u00adary 8. The manu\u00adfac\u00adtu\u00adrer has set a range of 26 to 30 euros. The total volume of the offe\u00adring is thus expec\u00adted to be around EUR 350 to 404 million. Since Wilhelm Beier (photo), the company\u2019s CEO, only wants to [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2018-01-30T16:36:06+00:00","og_image":[{"width":319,"height":252,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/01\/a-derma-e1517330055322.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"SDAX candidate: Dermapharm brings 25% percent to the stock exchange","datePublished":"2018-01-30T16:36:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/"},"wordCount":362,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/01\/a-derma-e1517330055322.jpg","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/","url":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/","name":"SDAX candidate: Dermapharm brings 25% percent to the stock exchange - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/01\/a-derma-e1517330055322.jpg","datePublished":"2018-01-30T16:36:06+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/01\/a-derma-e1517330055322.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/01\/a-derma-e1517330055322.jpg","width":319,"height":252},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/sdax-candidate-dermapharm-brings-25-percent-to-the-stock-exchange\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"SDAX candidate: Dermapharm brings 25% percent to the stock exchange"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/41964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=41964"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/41964\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/41972"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=41964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=41964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=41964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}